Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …

Background Blood eosinophil count has been proposed as a predictor of response to
inhaled corticosteroid (ICS) in the prevention of acute exacerbations of COPD. An optimal …

Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …

Background Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic
antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been …

Background and Purpose Combining inhaled corticosteroids (ICSs), long‐acting β2‐
adrenoceptor agonists (LABAs) and long‐acting muscarinic antagonists (LAMAs) is …

Background To date there are no head-to-head studies comparing different
mucolytic/antioxidant agents. Considering the inconsistent evidence resulting from the …

Objectives In some studies comparing triple with dual combination therapies in COPD there
might be a possible effect of inhaler bias resulting from different inhaler devices being used …

Chronic obstructive pulmonary disease (COPD) is associated with high morbidity and
mortality globally. Studies show that airway mucus hypersecretion strongly compromises …

Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

In recent years, heterogeneity in chronic obstructive pulmonary disease (COPD)
inflammatory patterns has been recognized as a basis for more precise treatment …